VHCP ABVX Holdings

Abivax is a clinical-stage biotechnology company focused on developing novel therapies that modulate the immune system to treat patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod, is an oral, small molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Obefazimod is currently being evaluated in a global Phase 3 clinical program for the treatment of moderately to severely active ulcerative colitis. Additionally, the company is progressing clinical trials for Crohn's disease and exploring other inflammatory indications. Abivax is headquartered in Paris, France, and is listed on both the Nasdaq and Euronext Paris exchanges.